Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly  Settings
RVNC Revance Therapeutics, Inc. daily Stock Chart
RVNC [NASD]
Revance Therapeutics, Inc.
Healthcare | Biotechnology | USA
financial highlights | statements
Index- P/E- EPS (ttm)-3.81 Insider Own0.80% Shs Outstand44.40M Perf Week2.43%
Market Cap561.66M Forward P/E- EPS next Y-3.70 Insider Trans-4.87% Shs Float42.00M Perf Month11.75%
Income-142.80M PEG- EPS next Q-0.91 Inst Own85.34% Short Float12.40% Perf Quarter-9.32%
Sales3.80M P/S147.81 EPS this Y1.60% Inst Trans0.09% Short Ratio12.52 Perf Half Y-37.35%
Book/sh5.32 P/B2.38 EPS next Y1.30% ROA- Target Price36.28 Perf Year-56.97%
Cash/sh6.10 P/C2.07 EPS next 5Y11.60% ROE- 52W Range10.37 - 30.60 Perf YTD-37.16%
Dividend- P/FCF- EPS past 5Y1.30% ROI-100.00% 52W High-58.66% Beta0.99
Dividend %- Quick Ratio8.10 Sales past 5Y43.30% Gross Margin- 52W Low21.99% ATR0.54
Employees170 Current Ratio8.10 Sales Q/Q50.00% Oper. Margin- RSI (14)57.42 Volatility4.18% 4.42%
OptionableYes Debt/Eq0.00 EPS Q/Q12.90% Profit Margin- Rel Volume1.26 Prev Close12.65
ShortableYes LT Debt/Eq0.00 EarningsAug 07 AMC Payout- Avg Volume415.82K Price12.65
Recom1.90 SMA202.58% SMA506.45% SMA200-25.91% Volume0 Change0.00%
Jun-11-19Initiated Barclays Overweight $28
Feb-15-19Initiated Wells Fargo Market Perform
Feb-14-19Initiated H.C. Wainwright Buy $25
Jan-29-19Initiated Stifel Buy $50
Nov-16-18Upgrade Guggenheim Neutral → Buy
Sep-17-18Downgrade JMP Securities Mkt Outperform → Mkt Perform
Apr-20-18Reiterated Mizuho Buy $54 → $48
Mar-27-18Initiated Needham Buy $42
Mar-05-18Initiated Goldman Buy $60
Jan-09-18Downgrade Guggenheim Buy → Neutral
Dec-06-17Reiterated Mizuho Buy $37 → $54
Dec-06-17Initiated Guggenheim Buy $42
Nov-27-17Initiated Barclays Overweight $31
Nov-17-17Initiated Mizuho Buy $37
Aug-22-17Initiated JMP Securities Mkt Outperform $34
Nov-29-16Initiated Aegis Capital Buy $28
Jun-14-16Reiterated SunTrust Buy $46 → $22
Jun-14-16Reiterated Piper Jaffray Overweight $54 → $35
Jun-14-16Downgrade Brean Capital Buy → Hold
Mar-23-16Initiated Sun Trust Rbsn Humphrey Buy $46
Jul-17-19 08:00AM  Revance Adds Life Sciences Audit Executive Chris Nolet to Board of Directors Business Wire
Jul-09-19 10:50AM  Did Changing Sentiment Drive Revance Therapeutics's (NASDAQ:RVNC) Share Price Down A Worrying 59%? Simply Wall St.
Jul-08-19 09:41AM  AbbVie (ABBV) Shares Down So Far This Year: Here's Why Zacks
Jun-26-19 02:06PM  Is Revance Therapeutics Inc (RVNC) A Good Stock To Buy? Insider Monkey
09:13AM  Here's Why Nobody's Happy About This $63 Billion Buyout Motley Fool
08:42AM  Revance Therapeutics (RVNC) Jumps: Stock Rises 5.2% Zacks
Jun-06-19 08:05AM  Revance Adds Iconic Brand Builder Jill Beraud to Board of Directors Business Wire
Jun-04-19 04:05PM  Revance to Participate in the Goldman Sachs 40th Annual Global Healthcare Conference Business Wire
May-22-19 01:33AM  Edited Transcript of RVNC earnings conference call or presentation 8-May-19 8:30pm GMT Thomson Reuters StreetEvents
May-14-19 04:05PM  Revance to Participate in the RBC Capital Markets 2019 Healthcare Conference Business Wire
May-09-19 10:23AM  Revance Therapeutics (RVNC) Q1 2019 Earnings Call Transcript Motley Fool
May-08-19 04:05PM  Revance Reports First Quarter 2019 Financial Results and Provides Corporate Update Business Wire
May-07-19 12:51PM  Is Revance Therapeutics Inc (RVNC) A Good Stock To Buy? Insider Monkey
May-01-19 02:21PM  A Spotlight On Revance Therapeutics, Inc.'s (NASDAQ:RVNC) Fundamentals Simply Wall St.
10:32AM  Will Revance Therapeutics (RVNC) Report Negative Earnings Next Week? What You Should Know Zacks
Apr-24-19 04:05PM  Revance to Release First Quarter 2019 Financial Results on Wednesday, May 8, 2019 Business Wire
Apr-09-19 08:00AM  Revance Appoints Former Allergan Marketing Veteran Taryn Conway as Vice President of Marketing Business Wire
Apr-08-19 04:05PM  SAKURA 3 Trial Results Presented on Podium at Worlds Largest Medical Aesthetic Conference Business Wire
Apr-04-19 05:46PM  Maker of Botox alternative turns toxin on crippling muscle disorder American City Business Journals
Apr-02-19 04:05PM  Revance to Participate in the Needham Healthcare Conference Business Wire
Apr-01-19 01:48PM  Does Revance Therapeutics, Inc. (NASDAQ:RVNC) Have A Volatile Share Price? Simply Wall St.
07:15AM  New Research: Key Drivers of Growth for Fresh Del Monte Produce, Baker Hughes, a GE company, HollyFrontier, Glaukos, HCI Group, and Revance Therapeutics Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
Mar-05-19 04:05PM  Revance to Participate in Upcoming Investor Conferences Business Wire
Mar-01-19 10:18AM  Edited Transcript of RVNC earnings conference call or presentation 26-Feb-19 9:30pm GMT Thomson Reuters StreetEvents
05:48AM  Revance Therapeutics Inc (RVNC) Files 10-K for the Fiscal Year Ended on December 31, 2018 GuruFocus.com
Feb-28-19 08:08AM  Need To Know: Revance Therapeutics, Inc. (NASDAQ:RVNC) Insiders Have Been Buying Shares Simply Wall St.
Feb-26-19 08:00PM  Revance Therapeutics Inc (RVNC) Q4 2018 Earnings Conference Call Transcript Motley Fool
04:05PM  Revance Releases Fourth Quarter and Full Year 2018 Results Business Wire
Feb-12-19 04:05PM  Revance to Release Fourth Quarter and Full Year 2018 Financial Results on Tuesday, February 26, 2019 Business Wire
Feb-11-19 09:00AM  CohBar Announces the Appointment of Dr. Phyllis Gardner to its Board of Directors GlobeNewswire
Feb-05-19 08:15AM  Allergan Stock Falls as FDA OK's Botox Rival for Frown Lines Zacks
Jan-28-19 07:23AM  What Kind Of Shareholders Own Revance Therapeutics, Inc. (NASDAQ:RVNC)? Simply Wall St.
Jan-25-19 07:30AM  Investor Expectations to Drive Momentum within International Paper, Gray Television, Nielsen Holdings Plc, e.l.f. Beauty, NIC, and Revance Therapeutics Discovering Underlying Factors of Influence GlobeNewswire
Jan-22-19 04:05PM  Revance Announces Closing of Public Offering of Common Stock Business Wire
Jan-17-19 06:50AM  Revance Announces Pricing of Public Offering of Common Stock Business Wire
Jan-16-19 08:24AM  The Daily Biotech Pulse: Revance Common Stock Offering, Adcom Catalyst For Amgen Benzinga -10.28%
Jan-15-19 04:17PM  Revance Announces Proposed Public Offering of Common Stock Business Wire
08:05AM  Revance Announces Ground-Breaking Data Presentations at Leading International Neurotoxin Conference Business Wire
Jan-07-19 08:05AM  Revance Highlights Recent Regulatory Progress and Provides Anticipated 2019 Milestones Business Wire
Dec-05-18 06:50AM  Today's Research Reports on Trending Tickers: Novelion Therapeutics and Revance Therapeutics ACCESSWIRE
Dec-04-18 02:08PM  Revance Therapeutics reaches licensing agreement with Fosun Pharmaceutical over botox formulation RT002 MarketWatch +19.47%
11:12AM  Revance Therapeutics' Botox rival succeeds in late-stage trial Reuters
08:27AM  Revance Therapeutics' frown lines treatment succeeds in late-stage trial Reuters
08:06AM  Revance Announces China Market License Agreement with Fosun Pharma for RT002 Business Wire
08:05AM  Revances RT002 Demonstrates Unprecedented Efficacy and Duration In Largest-Ever Aesthetic Neuromodulator Clinical Program Business Wire
Nov-27-18 07:40AM  Market Trends Toward New Normal in Palatin Technologies, Revance Therapeutics, Geo Group, QUANTENNA COMMS, The Navigators Group, and INVESCO MORTGAGE CAPITAL INC Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
Nov-20-18 04:05PM  Revance to Participate in Upcoming Investor Conferences Business Wire
Nov-16-18 03:48PM  Edited Transcript of RVNC earnings conference call or presentation 1-Nov-18 8:30pm GMT Thomson Reuters StreetEvents
Nov-15-18 12:20PM  Why Revance Therapeutics Incs (NASDAQ:RVNC) CEO Pay Matters To You Simply Wall St.
Nov-07-18 04:05PM  Revance to Participate in the Credit Suisse Healthcare Conference Business Wire
Nov-01-18 04:05PM  Revance Releases Third Quarter 2018 Results Business Wire +5.70%
Oct-18-18 04:05PM  Revance Therapeutics to Release Third Quarter 2018 Financial Results on Thursday, November 1, 2018 Business Wire
Oct-11-18 09:00AM  Investor Expectations to Drive Momentum within Materion, Iridium Communications, Natural Health Trends, Revance Therapeutics, Baxter International, and Alexion Pharmaceuticals Discovering Underlying Factors of Influence GlobeNewswire
08:30AM  Revance Therapeutics Appoints Tobin C. Schilke as Chief Financial Officer Business Wire
Sep-24-18 04:05PM  Revance to Participate in the Cantor Fitzgerald 2018 Global Healthcare Conference Business Wire
Sep-20-18 04:24PM  Revance Receives Great Place to Work Certification Business Wire
01:42PM  Before You Buy Revance Therapeutics Incs (NASDAQ:RVNC), Consider This Simply Wall St.
Sep-17-18 04:11PM  JMP: Changing Competitive Landscape Makes Revance Less Appealing Benzinga -8.28%
Sep-14-18 11:34AM  Allergan says revenue from aesthetics unit may double by 2025 Reuters
Aug-07-18 07:30AM  New Research Coverage Highlights Titan International, Revance Therapeutics, Ryerson Holding, Iridium Communications, Chase, and Peoples Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
Aug-03-18 11:19AM  Edited Transcript of RVNC earnings conference call or presentation 2-Aug-18 8:30pm GMT Thomson Reuters StreetEvents -9.75%
Aug-02-18 04:05PM  Revance Releases Second Quarter 2018 Results Business Wire
02:30PM  Revance Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Jul-19-18 04:05PM  Revance Therapeutics to Release Second Quarter 2018 Financial Results on Thursday, August 2, 2018 Business Wire
Jul-17-18 07:19AM  Revance Therapeutics Sees Hammer Chart Pattern: Time to Buy? Zacks
Jul-10-18 06:33PM  Cramer: Don't get your hopes up with the stock of Botox maker Allergan CNBC
Jun-21-18 04:05PM  Revance Doses First Patient in ASPEN Phase 3 Clinical Program of RT002 Injectable for the Treatment of Cervical Dystonia Business Wire
Jun-20-18 12:02PM  Top Growth Stocks in June Simply Wall St.
Jun-14-18 04:05PM  Revance to Participate in the JMP Securities Life Sciences Conference 2018 Business Wire
Jun-05-18 04:05PM  Revance to Participate in Upcoming Investor Conferences Business Wire
May-29-18 04:05PM  Revance to Participate in the Jefferies 2018 Global Healthcare Conference Business Wire -10.19%
07:00AM  Revance Announces Departure of Chief Financial Officer Business Wire
May-24-18 04:05PM  Revance Announces Publication of Positive 24-Week Duration of Effect Results from Cervical Dystonia Phase 2 Trial in Movement Disorders Clinical Practice Business Wire
May-18-18 12:02PM  High Growth NasdaqCM Stocks For The Day Simply Wall St.
May-17-18 04:18PM  Allergan's Meury Talks Market Expansion in Aesthetics TheStreet.com
May-15-18 04:05PM  Revance to Participate in the UBS Global Healthcare Conference Business Wire
May-10-18 03:46AM  Edited Transcript of RVNC earnings conference call or presentation 8-May-18 8:30pm GMT Thomson Reuters StreetEvents
May-09-18 04:05PM  Revance Therapeutics Announces Two Recent Additions to Its Management Team Business Wire
May-08-18 04:05PM  Revance Releases First Quarter 2018 Results Business Wire
May-02-18 07:50AM  Factors of Influence in 2018, Key Indicators and Opportunity within Independent Bank Group, Eclipse Resources, Stellus Capital Investment, International Bancshares, Portola Pharmaceuticals, and Revance Therapeutics New Research Emphasizes Economic Growth GlobeNewswire
May-01-18 04:05PM  Revance Therapeutics Expands Leadership Team, Appointing Caryn McDowell as SVP, General Counsel & Corporate Secretary CNBC
04:05PM  Revance Therapeutics Expands Leadership Team, Appointing Caryn McDowell as SVP, General Counsel & Corporate Secretary Business Wire
Apr-30-18 03:25PM  Revance Therapeutics Took the Least Resistance Path, Turned Lower TheStreet.com
Apr-25-18 04:05PM  Pivotal SAKURA Phase 3 Clinical Data to be Featured in Oral and Poster Presentations at The Aesthetic Meeting 2018 Business Wire
Apr-24-18 04:05PM  Revance Therapeutics to Release First Quarter 2018 Financial Results on Tuesday, May 8, 2018 Business Wire
Apr-23-18 12:22PM  Rival Botox Maker Says Patients Can't Wait for It to Hit Bloomberg
Apr-19-18 12:52PM  CEO of Botox competitor: 'With scale,' we think we'll hav... CNBC Videos
11:30AM  Revance Investor Day Highlights New Neuroscience Indications in Development Business Wire
09:24AM  Revance Therapeutics Stock Looks Ready for New Gains TheStreet.com
Apr-18-18 08:25PM  Revance Therapeutics: Cramer's Top Takeaways TheStreet.com
07:01PM  Cramer Remix: Wall Streets big problem with IBMs stock CNBC Videos
Apr-02-18 04:05PM  Revance Therapeutics Expands Commercialization Team to Gear Up for Product Launch of RT002 Injectable Business Wire
Mar-26-18 04:05PM  Revance to Host Investor Day on April 19, 2018 Business Wire
Mar-21-18 07:10AM  Edited Transcript of RVNC earnings conference call or presentation 28-Feb-18 9:30pm GMT Thomson Reuters StreetEvents
Mar-20-18 04:05PM  Revance to Participate in the Needham Healthcare Conference Business Wire
Mar-13-18 04:32PM  Cantor Fitzgerald Names 8 Upcoming Biotech Catalysts Benzinga
Mar-06-18 04:05PM  Revance to Participate in Upcoming Investor Conferences Business Wire
Mar-05-18 03:30PM  Goldman Sachs Sees 100% Upside In This Biopharma Company Benzinga
Mar-04-18 12:37PM  Mylan shares bounce on plans for Botox copycat, 2018 drug launches MarketWatch
11:33AM  Here's Why Allergan plc Stock Tanked 14.4% in February Motley Fool
Revance Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development, manufacture, and commercialization of novel neuromodulators for various aesthetic and therapeutic indications. The company's lead drug candidate is DaxibotulinumtoxinA for injection (DAXI), which is in phase III clinical trials to treat glabellar (frown) lines and cervical dystonia; and in phase II clinical trials for the treatment of plantar fasciitis, adult upper limb spasticity, and chronic migraine. It is also developing DAXI for forehead lines and lateral canthal lines; DaxibotulinumtoxinA Topical for therapeutic and aesthetic applications; and OnabotulinumtoxinA, a biosimilar to BOTOX. Revance Therapeutics, Inc. has a collaboration agreement with Mylan Ireland Limited for the development, manufacture, and commercialization of a biosimilar to BOTOX. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was founded in 1999 and is headquartered in Newark, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Browne L DanielCEO and PresidentMar 18Sale15.5111,613180,068151,193Mar 19 09:01 PM
Allouche CyrilPrincipal Accounting OfficerMar 18Sale15.484987,7096,400Mar 19 08:58 PM
Joshi AbhayChief Operating OfficerMar 14Option Exercise4.206662,79790,443Mar 18 08:34 PM
Browne L DanielCEO and PresidentFeb 19Sale17.685,44696,285168,943Feb 20 09:31 PM
Allouche CyrilPrincipal Accounting OfficerJan 22Option Exercise13.356258,3444,625Jan 23 09:38 PM
Allouche CyrilPrincipal Accounting OfficerJan 22Sale17.7762511,1064,000Jan 23 09:38 PM
Allouche CyrilPrincipal Accounting OfficerJan 03Sale19.483757,3054,000Jan 04 09:33 PM
Allouche CyrilPrincipal Accounting OfficerNov 20Sale20.6649110,1444,000Nov 21 06:30 PM
Allouche CyrilPrincipal Accounting OfficerNov 09Option Exercise13.352,18829,2106,938Nov 09 08:59 PM
Allouche CyrilPrincipal Accounting OfficerNov 09Sale23.722,18851,8994,750Nov 09 08:59 PM
open in yahoo | open in reuters | open in google